Search

everythinglearnresearchcommunity

for

Search:↓

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

Upadacitinib may effectively treat alopecia areata without side effects.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Erosive pustular dermatosis of the scalp can occur about 17 weeks after starting EGFR inhibitors, and early minocycline may help manage it.

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

Tofacitinib helped a woman regrow hair with no major side effects.

Significant progress was made in understanding PXE, but effective treatments are still needed.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

Gefitinib therapy can cause unusual hair growth on the nose.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.

Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.

The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.

Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.